Retacrit

Land: Europese Unie

Taal: Engels

Bron: EMA (European Medicines Agency)

Koop het nu

Bijsluiter Bijsluiter (PIL)
26-07-2023
Productkenmerken Productkenmerken (SPC)
26-07-2023

Werkstoffen:

epoetin zeta

Beschikbaar vanaf:

Pfizer Europe MA EEIG

ATC-code:

B03XA01

INN (Algemene Internationale Benaming):

epoetin zeta

Therapeutische categorie:

Other antianemic preparations

Therapeutisch gebied:

Anemia; Blood Transfusion, Autologous; Kidney Failure, Chronic; Cancer

therapeutische indicaties:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml).

Product samenvatting:

Revision: 31

Autorisatie-status:

Authorised

Autorisatie datum:

2007-12-18

Bijsluiter

                                91
B. PACKAGE LEAFLET
92
PACKAGE LEAFLET: INFORMATION FOR THE USER
RETACRIT 1 000 IU/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
RETACRIT 2 000 IU/0.6 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
RETACRIT 3 000 IU/0.9 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
RETACRIT 4 000 IU/0.4 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
RETACRIT 5 000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
RETACRIT 6 000 IU/0.6 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
RETACRIT 8 000 IU/0.8 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
RETACRIT 10 000 IU/1 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
RETACRIT 20 000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
RETACRIT 30 000 IU/0.75 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
RETACRIT 40 000 IU/1 MLSOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
epoetin zeta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
−
Keep this leaflet. You may need to read it again.
−
If you have any further questions, ask your doctor, pharmacist or
nurse.
−
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
−
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Retacrit is and what it is used for
2.
What you need to know before you use Retacrit
3.
How to use Retacrit
4.
Possible side effects
5.
How to store Retacrit
6.
Contents of the pack and other information
1.
WHAT RETACRIT IS AND WHAT IT IS USED FOR
Retacrit contains the active substance epoetin zeta – a protein that
stimulates the bone marrow to
produce more red blood cells which carry haemoglobin (a substance that
transports oxygen). Epoetin
zeta is a copy of the human protein erythropoietin
(ee-rith-roe-po-eh-tin) and acts in the same way.
•
RETACRIT IS USED TO TREAT SYMPTOMATIC ANAEMIA CA
                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Retacrit 1 000 IU/0.3 mL solution for injection in pre-filled syringe
Retacrit 2 000 IU/0.6 mL solution for injection in pre-filled syringe
Retacrit 3 000 IU/0.9 mL solution for injection in pre-filled syringe
Retacrit 4 000 IU/0.4 mL solution for injection in pre-filled syringe
Retacrit 5 000 IU/0.5 mL solution for injection in pre-filled syringe
Retacrit 6 000 IU/0.6 mL solution for injection in pre-filled syringe
Retacrit 8 000 IU/0.8 mL solution for injection in pre-filled syringe
Retacrit 10 000 IU/1 mL solution for injection in pre-filled syringe
Retacrit 20 000 IU/0.5 mL solution for injection in pre-filled syringe
Retacrit 30 000 IU/0.75 mL solution for injection in pre-filled
syringe
Retacrit 40 000 IU/1 mL solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Retacrit 1 000 IU/0.3 mL solution for injection in pre-filled syringe
1 pre-filled syringe with 0.3 mL solution for injection contains 1 000
international units (IU) epoetin
zeta* (recombinant human erythropoietin). The solution contains 3 333
IU epoetin zeta per mL.
Retacrit 2 000 IU/0.6 mL solution for injection in pre-filled syringe
1 pre-filled syringe with 0.6 mL solution for injection contains 2 000
international units (IU) epoetin
zeta* (recombinant human erythropoietin). The solution contains 3 333
IU epoetin zeta per mL.
Retacrit 3 000 IU/0.9 mL solution for injection in pre-filled syringe
1 pre-filled syringe with 0.9 mL solution for injection contains 3 000
international units (IU) epoetin
zeta* (recombinant human erythropoietin). The solution contains 3 333
IU epoetin zeta per mL.
Retacrit 4 000 IU/0.4 mL solution for injection in pre-filled syringe
1 pre-filled syringe with 0.4 mL solution for injection contains 4 000
international units (IU) epoetin
zeta* (recombinant human erythropoietin). The solution contains 10 000
IU epoetin zeta per mL.
Retacrit 5 000 IU/0.5 mL solution for injection in pre-filled syringe
1 pre-fill
                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Bulgaars 26-07-2023
Productkenmerken Productkenmerken Bulgaars 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Bulgaars 18-10-2011
Bijsluiter Bijsluiter Spaans 26-07-2023
Productkenmerken Productkenmerken Spaans 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Spaans 18-10-2011
Bijsluiter Bijsluiter Tsjechisch 26-07-2023
Productkenmerken Productkenmerken Tsjechisch 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Tsjechisch 18-10-2011
Bijsluiter Bijsluiter Deens 26-07-2023
Productkenmerken Productkenmerken Deens 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Deens 18-10-2011
Bijsluiter Bijsluiter Duits 26-07-2023
Productkenmerken Productkenmerken Duits 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Duits 18-10-2011
Bijsluiter Bijsluiter Estlands 26-07-2023
Productkenmerken Productkenmerken Estlands 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Estlands 18-10-2011
Bijsluiter Bijsluiter Grieks 26-07-2023
Productkenmerken Productkenmerken Grieks 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Grieks 18-10-2011
Bijsluiter Bijsluiter Frans 26-07-2023
Productkenmerken Productkenmerken Frans 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Frans 18-10-2011
Bijsluiter Bijsluiter Italiaans 26-07-2023
Productkenmerken Productkenmerken Italiaans 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Italiaans 18-10-2011
Bijsluiter Bijsluiter Letlands 26-07-2023
Productkenmerken Productkenmerken Letlands 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Letlands 18-10-2011
Bijsluiter Bijsluiter Litouws 26-07-2023
Productkenmerken Productkenmerken Litouws 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Litouws 18-10-2011
Bijsluiter Bijsluiter Hongaars 26-07-2023
Productkenmerken Productkenmerken Hongaars 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Hongaars 18-10-2011
Bijsluiter Bijsluiter Maltees 26-07-2023
Productkenmerken Productkenmerken Maltees 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Maltees 18-10-2011
Bijsluiter Bijsluiter Nederlands 26-07-2023
Productkenmerken Productkenmerken Nederlands 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Nederlands 18-10-2011
Bijsluiter Bijsluiter Pools 26-07-2023
Productkenmerken Productkenmerken Pools 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Pools 18-10-2011
Bijsluiter Bijsluiter Portugees 26-07-2023
Productkenmerken Productkenmerken Portugees 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Portugees 18-10-2011
Bijsluiter Bijsluiter Roemeens 26-07-2023
Productkenmerken Productkenmerken Roemeens 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Roemeens 18-10-2011
Bijsluiter Bijsluiter Slowaaks 26-07-2023
Productkenmerken Productkenmerken Slowaaks 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Slowaaks 18-10-2011
Bijsluiter Bijsluiter Sloveens 26-07-2023
Productkenmerken Productkenmerken Sloveens 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Sloveens 18-10-2011
Bijsluiter Bijsluiter Fins 26-07-2023
Productkenmerken Productkenmerken Fins 26-07-2023
Bijsluiter Bijsluiter Zweeds 26-07-2023
Productkenmerken Productkenmerken Zweeds 26-07-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Zweeds 18-10-2011
Bijsluiter Bijsluiter Noors 26-07-2023
Productkenmerken Productkenmerken Noors 26-07-2023
Bijsluiter Bijsluiter IJslands 26-07-2023
Productkenmerken Productkenmerken IJslands 26-07-2023
Bijsluiter Bijsluiter Kroatisch 26-07-2023
Productkenmerken Productkenmerken Kroatisch 26-07-2023

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten